Not exact matches
This method will facilitate the analysis
of patient tumors and the
selection of the most appropriate
therapy based on the individualized features
of each patient's
cancer subtype.
In addition to providing insights regarding
selection of treatment, this blood test may also prove helpful in assessing the presence
of residual disease, recurrence, or relapse and detection
of therapy - resistant
cancer cells more quickly than conventional tissue - based methods.
«This line
of work is starting to change our thinking about who and when — the timing and patient
selection for anti-androgen receptor
therapy in triple - negative breast
cancer,» says Valerie Barton, the study's first author and PhD candidate in the lab of CU Cancer Center investigator Jennifer Richer
cancer,» says Valerie Barton, the study's first author and PhD candidate in the lab
of CU
Cancer Center investigator Jennifer Richer
Cancer Center investigator Jennifer Richer, PhD.
«HER3 is thought to be an important mediator
of resistance to the HER2 inhibitors class
of anti-
cancer therapies, which are used to treat HER2 - positive breast
cancer representing approximately 20 percent
of all breast
cancers,» said principal author Eric P. Wehrenberg - Klee, MD, from Massachusetts General Hospital in Boston, Mass. «Imaging
of HER3 expression may allow for better understanding
of how prevalent HER3 over-expression is among HER2 positive breast
cancer patients, which in turn may allow for appropriate patient
selection for the addition
of HER3 inhibitors currently in clinical development.»
DENVER — Despite very encouraging progress in the development and use
of immunotherapy for patients with non-small cell lung
cancer, much confusion remains regarding patient
selection for each
therapy.
Pharmaceutical Industry Payments and Oncologists»
Selection of Targeted
Cancer Therapies in Medicare Beneficiaries.